Summary of findings – strontium ranelate vs placebo
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings – bisphosphonates changes adverse effects of treatment compared with placebo or no treatment (very low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).
Perampanel add‐on may leads to higher seizure freedom compared with placebo (low certainty).
Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).
Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).
Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).
Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).
Perampanel add‐on may leads to higher proportion of participants who experienced dizziness compared with placebo (low certainty).
The review found no eligible studies for this question.